| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 141 | 2025 | 2586 | 12.840 |
Why?
|
| Monocytes | 28 | 2024 | 277 | 5.310 |
Why?
|
| Anti-HIV Agents | 42 | 2021 | 486 | 4.910 |
Why?
|
| HIV-1 | 47 | 2025 | 755 | 4.110 |
Why?
|
| Antiretroviral Therapy, Highly Active | 34 | 2023 | 229 | 3.350 |
Why?
|
| AIDS Dementia Complex | 20 | 2024 | 116 | 2.950 |
Why?
|
| Leukocytes, Mononuclear | 17 | 2024 | 247 | 2.430 |
Why?
|
| Cognition Disorders | 17 | 2022 | 243 | 2.420 |
Why?
|
| CD4-Positive T-Lymphocytes | 11 | 2025 | 279 | 2.180 |
Why?
|
| Middle Aged | 105 | 2026 | 12222 | 2.130 |
Why?
|
| Humans | 180 | 2026 | 43102 | 1.910 |
Why?
|
| Insulin Resistance | 10 | 2020 | 201 | 1.880 |
Why?
|
| Male | 135 | 2026 | 23409 | 1.880 |
Why?
|
| Female | 125 | 2026 | 24698 | 1.710 |
Why?
|
| Atherosclerosis | 9 | 2020 | 169 | 1.680 |
Why?
|
| Anti-Retroviral Agents | 13 | 2022 | 160 | 1.620 |
Why?
|
| Viral Load | 21 | 2021 | 348 | 1.570 |
Why?
|
| Neuropsychological Tests | 13 | 2024 | 284 | 1.500 |
Why?
|
| Benzoxazines | 12 | 2022 | 47 | 1.500 |
Why?
|
| Adult | 97 | 2026 | 13872 | 1.430 |
Why?
|
| Aging | 13 | 2025 | 783 | 1.400 |
Why?
|
| DNA, Viral | 14 | 2016 | 311 | 1.390 |
Why?
|
| CD8-Positive T-Lymphocytes | 8 | 2024 | 184 | 1.370 |
Why?
|
| Mitochondria | 8 | 2020 | 523 | 1.340 |
Why?
|
| Inflammation | 16 | 2025 | 758 | 1.300 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 7 | 2019 | 31 | 1.250 |
Why?
|
| Cross-Sectional Studies | 36 | 2023 | 3156 | 1.210 |
Why?
|
| CD4 Lymphocyte Count | 23 | 2021 | 201 | 1.210 |
Why?
|
| Cognition | 8 | 2018 | 473 | 1.190 |
Why?
|
| Adipose Tissue | 4 | 2016 | 182 | 1.170 |
Why?
|
| Peripheral Nervous System Diseases | 4 | 2015 | 21 | 1.140 |
Why?
|
| Carotid Artery Diseases | 2 | 2020 | 26 | 1.130 |
Why?
|
| Vitamin D | 3 | 2016 | 196 | 1.080 |
Why?
|
| DNA, Mitochondrial | 6 | 2019 | 191 | 1.060 |
Why?
|
| Receptors, Immunologic | 4 | 2024 | 73 | 1.060 |
Why?
|
| Hawaii | 23 | 2022 | 2011 | 1.050 |
Why?
|
| RNA, Viral | 18 | 2020 | 321 | 1.050 |
Why?
|
| Brain | 8 | 2024 | 1472 | 1.010 |
Why?
|
| Cohort Studies | 29 | 2022 | 1759 | 1.000 |
Why?
|
| HIV Seropositivity | 7 | 2014 | 196 | 0.980 |
Why?
|
| Cardiovascular Diseases | 7 | 2022 | 749 | 0.980 |
Why?
|
| Metformin | 3 | 2023 | 75 | 0.920 |
Why?
|
| Acquired Immunodeficiency Syndrome | 8 | 2014 | 226 | 0.910 |
Why?
|
| Coronary Artery Disease | 3 | 2019 | 163 | 0.900 |
Why?
|
| Risk Factors | 20 | 2023 | 3994 | 0.880 |
Why?
|
| HIV | 9 | 2021 | 100 | 0.860 |
Why?
|
| Oxidative Phosphorylation | 3 | 2020 | 60 | 0.860 |
Why?
|
| Granulocytes | 2 | 2023 | 26 | 0.860 |
Why?
|
| Calcium | 4 | 2020 | 491 | 0.840 |
Why?
|
| Latent Tuberculosis | 1 | 2023 | 4 | 0.830 |
Why?
|
| Atrophy | 4 | 2024 | 51 | 0.820 |
Why?
|
| Receptors, CCR5 | 4 | 2018 | 64 | 0.800 |
Why?
|
| Guideline Adherence | 1 | 2023 | 98 | 0.790 |
Why?
|
| Polyneuropathies | 2 | 2013 | 9 | 0.780 |
Why?
|
| Tuberculosis | 1 | 2023 | 78 | 0.770 |
Why?
|
| Viremia | 5 | 2021 | 44 | 0.760 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 539 | 0.750 |
Why?
|
| Lymphocyte Activation | 6 | 2024 | 249 | 0.750 |
Why?
|
| Niacin | 3 | 2013 | 23 | 0.740 |
Why?
|
| Receptors, CCR2 | 4 | 2018 | 28 | 0.730 |
Why?
|
| Coronary Vessels | 3 | 2020 | 92 | 0.730 |
Why?
|
| Central Nervous System Diseases | 2 | 2019 | 32 | 0.720 |
Why?
|
| Bone Diseases | 2 | 2020 | 18 | 0.720 |
Why?
|
| Cerebrovascular Disorders | 3 | 2012 | 43 | 0.710 |
Why?
|
| Cytokines | 7 | 2023 | 678 | 0.710 |
Why?
|
| CD4-CD8 Ratio | 3 | 2020 | 29 | 0.690 |
Why?
|
| Hepatitis C | 2 | 2022 | 139 | 0.690 |
Why?
|
| Gonorrhea | 1 | 2021 | 24 | 0.690 |
Why?
|
| Skin | 3 | 2015 | 187 | 0.670 |
Why?
|
| Albuminuria | 3 | 2016 | 78 | 0.670 |
Why?
|
| Hospitalization | 2 | 2014 | 485 | 0.670 |
Why?
|
| Hippocampus | 2 | 2016 | 594 | 0.660 |
Why?
|
| Carotid Stenosis | 1 | 2020 | 16 | 0.660 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 193 | 0.660 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 386 | 0.650 |
Why?
|
| Cyclohexanes | 2 | 2023 | 30 | 0.640 |
Why?
|
| Reverse Transcriptase Inhibitors | 10 | 2019 | 57 | 0.620 |
Why?
|
| Body Fat Distribution | 3 | 2016 | 26 | 0.620 |
Why?
|
| Cyclopropanes | 12 | 2022 | 46 | 0.610 |
Why?
|
| Carotid Arteries | 3 | 2022 | 36 | 0.610 |
Why?
|
| Alkynes | 12 | 2022 | 52 | 0.610 |
Why?
|
| Macrophages | 3 | 2014 | 529 | 0.600 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2021 | 174 | 0.600 |
Why?
|
| Nerve Fibers | 3 | 2014 | 37 | 0.600 |
Why?
|
| Triazoles | 2 | 2023 | 102 | 0.600 |
Why?
|
| Lipoproteins, LDL | 2 | 2020 | 67 | 0.590 |
Why?
|
| Aged | 26 | 2026 | 8214 | 0.550 |
Why?
|
| Zidovudine | 8 | 2015 | 32 | 0.550 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2024 | 587 | 0.530 |
Why?
|
| Interleukin-6 | 4 | 2020 | 165 | 0.500 |
Why?
|
| Autonomic Nervous System Diseases | 2 | 2013 | 12 | 0.500 |
Why?
|
| Pilot Projects | 8 | 2025 | 760 | 0.490 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2015 | 13 | 0.490 |
Why?
|
| Chemokine CCL2 | 2 | 2016 | 95 | 0.490 |
Why?
|
| Bilirubin | 1 | 2016 | 18 | 0.480 |
Why?
|
| Deoxyguanosine | 1 | 2016 | 36 | 0.480 |
Why?
|
| Calcinosis | 2 | 2016 | 62 | 0.470 |
Why?
|
| Oxidative Stress | 4 | 2019 | 1003 | 0.460 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 97 | 0.460 |
Why?
|
| Sensory Receptor Cells | 1 | 2015 | 34 | 0.450 |
Why?
|
| Thailand | 10 | 2015 | 51 | 0.440 |
Why?
|
| Plasma | 2 | 2017 | 38 | 0.430 |
Why?
|
| Lipoproteins, HDL | 1 | 2014 | 48 | 0.430 |
Why?
|
| C-Reactive Protein | 3 | 2015 | 167 | 0.430 |
Why?
|
| Vasodilation | 2 | 2015 | 64 | 0.430 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2020 | 384 | 0.430 |
Why?
|
| Retrospective Studies | 13 | 2023 | 2544 | 0.420 |
Why?
|
| Age Factors | 8 | 2025 | 1154 | 0.420 |
Why?
|
| Mycoses | 4 | 2017 | 31 | 0.420 |
Why?
|
| AIDS-Related Opportunistic Infections | 5 | 2017 | 44 | 0.410 |
Why?
|
| Mitochondrial Proteins | 2 | 2019 | 118 | 0.410 |
Why?
|
| Reflex | 1 | 2013 | 29 | 0.410 |
Why?
|
| Dementia | 2 | 2014 | 160 | 0.410 |
Why?
|
| Social Work | 1 | 2013 | 53 | 0.400 |
Why?
|
| Drug Resistance, Viral | 7 | 2017 | 67 | 0.400 |
Why?
|
| Receptors, IgG | 5 | 2022 | 53 | 0.390 |
Why?
|
| Cholesterol | 1 | 2014 | 232 | 0.390 |
Why?
|
| Body Mass Index | 3 | 2013 | 925 | 0.380 |
Why?
|
| Glomerular Filtration Rate | 3 | 2023 | 147 | 0.380 |
Why?
|
| Withholding Treatment | 3 | 2012 | 30 | 0.380 |
Why?
|
| Caudate Nucleus | 1 | 2012 | 22 | 0.370 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 107 | 0.360 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2012 | 38 | 0.360 |
Why?
|
| Blood Glucose | 5 | 2020 | 389 | 0.350 |
Why?
|
| Endothelial Cells | 2 | 2018 | 329 | 0.350 |
Why?
|
| Vascular Diseases | 1 | 2011 | 33 | 0.350 |
Why?
|
| Antigens, CD | 4 | 2021 | 127 | 0.350 |
Why?
|
| Polymerase Chain Reaction | 5 | 2016 | 455 | 0.340 |
Why?
|
| Longitudinal Studies | 8 | 2019 | 1063 | 0.330 |
Why?
|
| AIDS-Associated Nephropathy | 1 | 2010 | 14 | 0.330 |
Why?
|
| Subcutaneous Fat | 2 | 2019 | 19 | 0.330 |
Why?
|
| Hypertriglyceridemia | 1 | 2010 | 16 | 0.320 |
Why?
|
| Hepacivirus | 2 | 2022 | 74 | 0.320 |
Why?
|
| Cerebral Cortex | 4 | 2017 | 306 | 0.320 |
Why?
|
| Models, Immunological | 1 | 2010 | 21 | 0.320 |
Why?
|
| Vietnam | 6 | 2022 | 62 | 0.320 |
Why?
|
| Cholesterol, HDL | 1 | 2010 | 99 | 0.310 |
Why?
|
| Complement System Proteins | 2 | 2025 | 25 | 0.310 |
Why?
|
| Lipoproteins | 3 | 2014 | 70 | 0.310 |
Why?
|
| HLA-DR Antigens | 2 | 2022 | 23 | 0.310 |
Why?
|
| Lipodystrophy | 3 | 2006 | 7 | 0.300 |
Why?
|
| Healthcare Disparities | 1 | 2014 | 590 | 0.290 |
Why?
|
| Mutation | 3 | 2021 | 1177 | 0.290 |
Why?
|
| Motor Skills Disorders | 1 | 2008 | 4 | 0.290 |
Why?
|
| Leukocyte Count | 3 | 2019 | 69 | 0.290 |
Why?
|
| Aged, 80 and over | 6 | 2025 | 2853 | 0.280 |
Why?
|
| Renin-Angiotensin System | 2 | 2025 | 48 | 0.280 |
Why?
|
| Apolipoprotein E4 | 1 | 2008 | 67 | 0.270 |
Why?
|
| Needs Assessment | 1 | 2009 | 178 | 0.270 |
Why?
|
| HIV Seronegativity | 2 | 2005 | 41 | 0.270 |
Why?
|
| Galectins | 2 | 2018 | 30 | 0.260 |
Why?
|
| Prospective Studies | 12 | 2019 | 1600 | 0.260 |
Why?
|
| Blood Platelets | 3 | 2025 | 81 | 0.260 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 440 | 0.260 |
Why?
|
| Prevalence | 9 | 2025 | 1612 | 0.260 |
Why?
|
| Talaromyces | 2 | 2017 | 2 | 0.260 |
Why?
|
| Penicillium | 3 | 2011 | 6 | 0.260 |
Why?
|
| DNA Methylation | 3 | 2023 | 403 | 0.250 |
Why?
|
| Oxygen Consumption | 3 | 2017 | 110 | 0.250 |
Why?
|
| Central Nervous System | 2 | 2018 | 152 | 0.250 |
Why?
|
| Phenotype | 4 | 2022 | 780 | 0.250 |
Why?
|
| Neutrophils | 2 | 2025 | 145 | 0.240 |
Why?
|
| Prefrontal Cortex | 2 | 2018 | 164 | 0.240 |
Why?
|
| Population | 1 | 2005 | 8 | 0.240 |
Why?
|
| Antifungal Agents | 4 | 2017 | 169 | 0.240 |
Why?
|
| Heart Rate | 6 | 2017 | 266 | 0.240 |
Why?
|
| Blood Coagulation | 1 | 2025 | 29 | 0.230 |
Why?
|
| Adolescent | 10 | 2025 | 6081 | 0.230 |
Why?
|
| Proteins | 1 | 2008 | 382 | 0.230 |
Why?
|
| Stavudine | 3 | 2015 | 13 | 0.230 |
Why?
|
| Mitochondrial Diseases | 1 | 2005 | 20 | 0.230 |
Why?
|
| HIV Wasting Syndrome | 1 | 2005 | 8 | 0.230 |
Why?
|
| Metabolic Diseases | 1 | 2026 | 40 | 0.230 |
Why?
|
| Physical Fitness | 2 | 2017 | 90 | 0.230 |
Why?
|
| Immunophenotyping | 2 | 2016 | 57 | 0.230 |
Why?
|
| Young Adult | 11 | 2025 | 5080 | 0.230 |
Why?
|
| Fatty Liver | 1 | 2026 | 77 | 0.220 |
Why?
|
| Neopterin | 2 | 2022 | 13 | 0.220 |
Why?
|
| B-Lymphocytes | 1 | 2025 | 189 | 0.220 |
Why?
|
| HIV Protease Inhibitors | 3 | 2015 | 24 | 0.210 |
Why?
|
| Killer Cells, Natural | 2 | 2022 | 104 | 0.210 |
Why?
|
| Myeloid Cells | 2 | 2024 | 31 | 0.210 |
Why?
|
| Pulmonary Fibrosis | 1 | 2024 | 38 | 0.200 |
Why?
|
| Galectin 3 | 1 | 2023 | 30 | 0.200 |
Why?
|
| Weight Gain | 1 | 2004 | 139 | 0.200 |
Why?
|
| Lamivudine | 6 | 2012 | 22 | 0.200 |
Why?
|
| Brachial Artery | 2 | 2015 | 27 | 0.200 |
Why?
|
| Adiposity | 1 | 2004 | 157 | 0.200 |
Why?
|
| Dideoxynucleosides | 5 | 2010 | 11 | 0.200 |
Why?
|
| Fetal Blood | 1 | 2003 | 48 | 0.190 |
Why?
|
| Health Status Disparities | 2 | 2026 | 719 | 0.190 |
Why?
|
| Respiratory Tract Infections | 1 | 2022 | 36 | 0.190 |
Why?
|
| Treatment Outcome | 10 | 2015 | 1604 | 0.190 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2003 | 74 | 0.190 |
Why?
|
| Flow Cytometry | 5 | 2016 | 411 | 0.190 |
Why?
|
| Double-Blind Method | 7 | 2025 | 317 | 0.190 |
Why?
|
| Histones | 1 | 2023 | 197 | 0.180 |
Why?
|
| Placenta | 1 | 2003 | 117 | 0.180 |
Why?
|
| Delayed-Action Preparations | 3 | 2013 | 74 | 0.180 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2003 | 117 | 0.180 |
Why?
|
| Phylogeny | 2 | 2022 | 769 | 0.170 |
Why?
|
| Antibodies, Neutralizing | 2 | 2012 | 127 | 0.170 |
Why?
|
| Cystatin C | 1 | 2020 | 25 | 0.170 |
Why?
|
| Case-Control Studies | 7 | 2019 | 1285 | 0.170 |
Why?
|
| Electrocardiography | 3 | 2017 | 185 | 0.170 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 719 | 0.170 |
Why?
|
| Host-Pathogen Interactions | 2 | 2020 | 209 | 0.160 |
Why?
|
| Erythrocyte Indices | 2 | 2018 | 14 | 0.160 |
Why?
|
| Genome, Viral | 1 | 2021 | 119 | 0.160 |
Why?
|
| Fibrosis | 2 | 2022 | 169 | 0.160 |
Why?
|
| Interferon Regulatory Factors | 1 | 2019 | 18 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2021 | 117 | 0.160 |
Why?
|
| Itraconazole | 2 | 2017 | 13 | 0.150 |
Why?
|
| Disease Progression | 6 | 2024 | 667 | 0.150 |
Why?
|
| Uganda | 1 | 2019 | 22 | 0.150 |
Why?
|
| Membrane Glycoproteins | 2 | 2022 | 224 | 0.150 |
Why?
|
| Autonomic Nervous System | 2 | 2012 | 39 | 0.150 |
Why?
|
| Genotype | 3 | 2019 | 800 | 0.150 |
Why?
|
| Adipocytes | 1 | 2019 | 60 | 0.150 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2014 | 301 | 0.150 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 22 | 0.150 |
Why?
|
| Genetic Markers | 1 | 2019 | 150 | 0.150 |
Why?
|
| Gene Expression | 2 | 2014 | 701 | 0.150 |
Why?
|
| E-Selectin | 1 | 2018 | 23 | 0.140 |
Why?
|
| Hepatitis C, Chronic | 1 | 2019 | 44 | 0.140 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 206 | 0.140 |
Why?
|
| Interleukin-1beta | 2 | 2020 | 75 | 0.140 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 146 | 0.140 |
Why?
|
| Macrophage Activation | 1 | 2018 | 61 | 0.140 |
Why?
|
| Erythrocytes | 1 | 2018 | 126 | 0.140 |
Why?
|
| Neural Pathways | 1 | 2018 | 138 | 0.140 |
Why?
|
| Imidazoles | 1 | 2018 | 142 | 0.130 |
Why?
|
| Deoxycholic Acid | 1 | 2017 | 8 | 0.130 |
Why?
|
| Research Design | 2 | 2013 | 385 | 0.130 |
Why?
|
| Amphotericin B | 1 | 2017 | 25 | 0.130 |
Why?
|
| Cell Respiration | 1 | 2017 | 35 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2016 | 245 | 0.130 |
Why?
|
| Incidence | 5 | 2012 | 1078 | 0.130 |
Why?
|
| Sympathetic Nervous System | 1 | 2017 | 57 | 0.130 |
Why?
|
| Prognosis | 2 | 2019 | 861 | 0.130 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2017 | 23 | 0.130 |
Why?
|
| Statistics, Nonparametric | 3 | 2012 | 113 | 0.130 |
Why?
|
| Hypertension | 1 | 2003 | 835 | 0.120 |
Why?
|
| Carotid Artery, Common | 1 | 2016 | 9 | 0.120 |
Why?
|
| HIV Reverse Transcriptase | 3 | 2017 | 35 | 0.120 |
Why?
|
| Nerve Net | 1 | 2017 | 101 | 0.120 |
Why?
|
| Virus Activation | 1 | 2016 | 38 | 0.120 |
Why?
|
| Virus Latency | 1 | 2016 | 49 | 0.120 |
Why?
|
| Body Composition | 2 | 2007 | 159 | 0.120 |
Why?
|
| Reference Values | 2 | 2013 | 211 | 0.120 |
Why?
|
| Energy Metabolism | 1 | 2017 | 187 | 0.120 |
Why?
|
| Absorptiometry, Photon | 1 | 2016 | 76 | 0.120 |
Why?
|
| Proviruses | 2 | 2007 | 35 | 0.120 |
Why?
|
| Lactic Acid | 2 | 2007 | 112 | 0.120 |
Why?
|
| Memory | 3 | 2012 | 174 | 0.120 |
Why?
|
| Chronic Disease | 2 | 2016 | 549 | 0.120 |
Why?
|
| Blood Pressure | 2 | 2013 | 666 | 0.120 |
Why?
|
| Diagnostic Equipment | 1 | 2015 | 3 | 0.120 |
Why?
|
| Serum Amyloid P-Component | 1 | 2015 | 21 | 0.120 |
Why?
|
| Fungal Proteins | 1 | 2016 | 142 | 0.120 |
Why?
|
| Lymphocyte Count | 2 | 2014 | 46 | 0.120 |
Why?
|
| Homosexuality, Male | 1 | 2021 | 486 | 0.120 |
Why?
|
| Antiviral Agents | 2 | 2010 | 195 | 0.120 |
Why?
|
| Amblyopia | 1 | 2015 | 13 | 0.120 |
Why?
|
| Seasons | 2 | 2013 | 139 | 0.120 |
Why?
|
| Leg | 1 | 2015 | 19 | 0.120 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2014 | 91 | 0.110 |
Why?
|
| Vision Screening | 1 | 2015 | 21 | 0.110 |
Why?
|
| Acute-Phase Proteins | 1 | 2014 | 15 | 0.110 |
Why?
|
| HIV Antibodies | 2 | 2012 | 24 | 0.110 |
Why?
|
| Epidermis | 1 | 2014 | 23 | 0.110 |
Why?
|
| Psychomotor Performance | 2 | 2012 | 159 | 0.110 |
Why?
|
| HIV-2 | 1 | 2014 | 9 | 0.110 |
Why?
|
| Nevirapine | 2 | 2012 | 8 | 0.110 |
Why?
|
| Disease Management | 1 | 2014 | 70 | 0.100 |
Why?
|
| Age Distribution | 2 | 2012 | 249 | 0.100 |
Why?
|
| Japan | 1 | 2014 | 348 | 0.100 |
Why?
|
| Educational Status | 2 | 2012 | 339 | 0.100 |
Why?
|
| Ferrosoferric Oxide | 1 | 2013 | 13 | 0.100 |
Why?
|
| Particle Size | 1 | 2014 | 272 | 0.100 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 77 | 0.100 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2013 | 32 | 0.100 |
Why?
|
| DNA Damage | 1 | 2016 | 356 | 0.100 |
Why?
|
| Oxygen | 1 | 2014 | 218 | 0.100 |
Why?
|
| Trail Making Test | 1 | 2013 | 3 | 0.100 |
Why?
|
| Follow-Up Studies | 4 | 2026 | 1067 | 0.100 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 532 | 0.100 |
Why?
|
| Cerebellum | 1 | 2013 | 79 | 0.100 |
Why?
|
| Depression | 2 | 2018 | 863 | 0.100 |
Why?
|
| Receptors, Chemokine | 1 | 2013 | 72 | 0.090 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2012 | 27 | 0.090 |
Why?
|
| Phosphorylation | 1 | 2014 | 986 | 0.090 |
Why?
|
| Adenine | 2 | 2012 | 46 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 58 | 0.090 |
Why?
|
| Arteries | 1 | 2011 | 81 | 0.090 |
Why?
|
| Psychological Tests | 1 | 2011 | 56 | 0.090 |
Why?
|
| Exercise | 1 | 2017 | 692 | 0.090 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2010 | 1 | 0.080 |
Why?
|
| Anus Diseases | 1 | 2011 | 17 | 0.080 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 11 | 0.080 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 15 | 0.080 |
Why?
|
| Anal Canal | 1 | 2011 | 32 | 0.080 |
Why?
|
| Recurrence | 1 | 2011 | 152 | 0.080 |
Why?
|
| Antigen Presentation | 1 | 2010 | 58 | 0.080 |
Why?
|
| Liver Function Tests | 1 | 2010 | 19 | 0.080 |
Why?
|
| Time Factors | 4 | 2017 | 1857 | 0.080 |
Why?
|
| Virus Replication | 2 | 2011 | 318 | 0.080 |
Why?
|
| Bacteriocins | 1 | 2009 | 7 | 0.080 |
Why?
|
| Cryptococcus neoformans | 1 | 2010 | 62 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2010 | 760 | 0.080 |
Why?
|
| Mutation, Missense | 1 | 2010 | 91 | 0.080 |
Why?
|
| Canarypox virus | 1 | 2009 | 4 | 0.080 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2009 | 2 | 0.080 |
Why?
|
| Vaccinia virus | 1 | 2009 | 13 | 0.070 |
Why?
|
| Leprosy | 1 | 2009 | 4 | 0.070 |
Why?
|
| United States | 2 | 2026 | 5205 | 0.070 |
Why?
|
| Neurologic Examination | 1 | 2008 | 30 | 0.070 |
Why?
|
| Health Care Surveys | 1 | 2009 | 152 | 0.070 |
Why?
|
| Glucose | 1 | 2010 | 244 | 0.070 |
Why?
|
| Lipids | 2 | 2007 | 256 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2010 | 375 | 0.070 |
Why?
|
| Statistics as Topic | 1 | 2008 | 123 | 0.070 |
Why?
|
| Immunoassay | 1 | 2008 | 74 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2010 | 182 | 0.070 |
Why?
|
| Oxazines | 2 | 2006 | 32 | 0.070 |
Why?
|
| Survival Rate | 1 | 2008 | 355 | 0.070 |
Why?
|
| Health Services Research | 1 | 2008 | 161 | 0.070 |
Why?
|
| Treatment Failure | 3 | 2015 | 60 | 0.070 |
Why?
|
| Pyrimidinones | 1 | 2007 | 15 | 0.070 |
Why?
|
| Ritonavir | 1 | 2007 | 15 | 0.070 |
Why?
|
| Interviews as Topic | 1 | 2009 | 452 | 0.070 |
Why?
|
| Interleukin-8 | 2 | 2020 | 74 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2008 | 154 | 0.070 |
Why?
|
| Anemia, Macrocytic | 1 | 2007 | 2 | 0.060 |
Why?
|
| Mental Status Schedule | 1 | 2006 | 18 | 0.060 |
Why?
|
| Abdominal Fat | 1 | 2006 | 21 | 0.060 |
Why?
|
| Sex Factors | 1 | 2010 | 1028 | 0.060 |
Why?
|
| Acidosis, Lactic | 1 | 2006 | 6 | 0.060 |
Why?
|
| Body Weight | 2 | 2006 | 429 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2022 | 306 | 0.060 |
Why?
|
| Logistic Models | 3 | 2019 | 1009 | 0.060 |
Why?
|
| Regression Analysis | 3 | 2014 | 490 | 0.060 |
Why?
|
| Cell Adhesion Molecules | 2 | 2018 | 83 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 458 | 0.060 |
Why?
|
| Palatine Tonsil | 1 | 2025 | 7 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 17 | 0.060 |
Why?
|
| Angiotensin I | 1 | 2025 | 9 | 0.060 |
Why?
|
| Dyslipidemias | 1 | 2006 | 48 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2011 | 376 | 0.060 |
Why?
|
| Platelet Activation | 1 | 2025 | 6 | 0.060 |
Why?
|
| Infant | 3 | 2019 | 1175 | 0.060 |
Why?
|
| Germinal Center | 1 | 2025 | 12 | 0.060 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2025 | 30 | 0.060 |
Why?
|
| Neutrophil Activation | 1 | 2025 | 10 | 0.060 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2025 | 41 | 0.060 |
Why?
|
| Testosterone | 1 | 2006 | 211 | 0.060 |
Why?
|
| Indians, North American | 1 | 2008 | 192 | 0.060 |
Why?
|
| Glucose Intolerance | 1 | 2005 | 40 | 0.060 |
Why?
|
| Comorbidity | 3 | 2016 | 737 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2019 | 1546 | 0.060 |
Why?
|
| Independent Living | 1 | 2025 | 47 | 0.060 |
Why?
|
| Acetylcarnitine | 1 | 2004 | 7 | 0.060 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2025 | 93 | 0.060 |
Why?
|
| Immunity, Innate | 2 | 2019 | 171 | 0.050 |
Why?
|
| Drug Therapy, Combination | 4 | 2007 | 234 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2005 | 102 | 0.050 |
Why?
|
| Asia, Southeastern | 2 | 2016 | 12 | 0.050 |
Why?
|
| Base Sequence | 2 | 2003 | 983 | 0.050 |
Why?
|
| Computer Systems | 1 | 2004 | 19 | 0.050 |
Why?
|
| Hemostasis | 1 | 2023 | 6 | 0.050 |
Why?
|
| Nucleosides | 1 | 2004 | 30 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2025 | 257 | 0.050 |
Why?
|
| Animals | 5 | 2023 | 16992 | 0.050 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2026 | 163 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2025 | 307 | 0.050 |
Why?
|
| Bystander Effect | 1 | 2023 | 15 | 0.050 |
Why?
|
| Prednisolone | 1 | 2003 | 16 | 0.050 |
Why?
|
| Leukocytes | 1 | 2023 | 80 | 0.050 |
Why?
|
| Sequence Analysis, RNA | 1 | 2024 | 115 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2025 | 536 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2026 | 224 | 0.050 |
Why?
|
| ROC Curve | 2 | 2013 | 159 | 0.050 |
Why?
|
| Hepatitis C Antibodies | 1 | 2002 | 10 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2024 | 183 | 0.050 |
Why?
|
| Epidemiologic Studies | 1 | 2002 | 33 | 0.050 |
Why?
|
| Chemokines | 1 | 2023 | 96 | 0.050 |
Why?
|
| DNA Primers | 1 | 2003 | 294 | 0.050 |
Why?
|
| Receptors, CCR7 | 1 | 2022 | 19 | 0.050 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 78 | 0.050 |
Why?
|
| Pregnancy | 2 | 2011 | 1772 | 0.050 |
Why?
|
| Torque teno virus | 1 | 2002 | 9 | 0.050 |
Why?
|
| Antigens, CD19 | 1 | 2002 | 16 | 0.050 |
Why?
|
| Haplotypes | 2 | 2014 | 197 | 0.050 |
Why?
|
| Epitopes | 1 | 2022 | 157 | 0.050 |
Why?
|
| DNA Virus Infections | 1 | 2002 | 16 | 0.050 |
Why?
|
| Models, Biological | 1 | 2005 | 712 | 0.050 |
Why?
|
| Testis | 1 | 2023 | 207 | 0.050 |
Why?
|
| Actins | 1 | 2022 | 164 | 0.040 |
Why?
|
| Viral Envelope Proteins | 1 | 2022 | 91 | 0.040 |
Why?
|
| Exercise Test | 2 | 2014 | 74 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 734 | 0.040 |
Why?
|
| Patient Participation | 1 | 2002 | 94 | 0.040 |
Why?
|
| Child | 3 | 2019 | 3443 | 0.040 |
Why?
|
| Virus Integration | 1 | 2002 | 65 | 0.040 |
Why?
|
| Patient Compliance | 2 | 2017 | 233 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2002 | 341 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2021 | 26 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2019 | 863 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2023 | 665 | 0.040 |
Why?
|
| Fusobacteria | 1 | 2020 | 4 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2023 | 291 | 0.040 |
Why?
|
| Autoantigens | 1 | 2021 | 87 | 0.040 |
Why?
|
| Fasting | 1 | 2020 | 56 | 0.040 |
Why?
|
| Verbal Learning | 2 | 2012 | 18 | 0.040 |
Why?
|
| Antirheumatic Agents | 1 | 2020 | 37 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 153 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2018 | 1621 | 0.040 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2019 | 18 | 0.040 |
Why?
|
| Electron Transport Complex IV | 1 | 2019 | 41 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 259 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2009 | 2157 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 203 | 0.040 |
Why?
|
| Algorithms | 1 | 2022 | 509 | 0.040 |
Why?
|
| Organ Size | 1 | 2019 | 170 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2012 | 575 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2019 | 79 | 0.040 |
Why?
|
| Cell Movement | 2 | 2013 | 655 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 109 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2021 | 307 | 0.040 |
Why?
|
| Acute Disease | 1 | 2019 | 155 | 0.040 |
Why?
|
| Sulfoxides | 1 | 2018 | 18 | 0.040 |
Why?
|
| Rest | 1 | 2018 | 32 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2002 | 1234 | 0.040 |
Why?
|
| Obesity | 1 | 2006 | 1151 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 149 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 127 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2009 | 518 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2017 | 53 | 0.030 |
Why?
|
| Aorta | 1 | 2018 | 198 | 0.030 |
Why?
|
| Philippines | 1 | 2017 | 81 | 0.030 |
Why?
|
| Creatinine | 1 | 2017 | 102 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2017 | 104 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2017 | 260 | 0.030 |
Why?
|
| Mice | 2 | 2023 | 6644 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2019 | 972 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2016 | 135 | 0.030 |
Why?
|
| Cell Separation | 1 | 2016 | 94 | 0.030 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2016 | 57 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2016 | 139 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 883 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2016 | 592 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 287 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2013 | 52 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2014 | 195 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2013 | 107 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 259 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2012 | 113 | 0.020 |
Why?
|
| Cross-Cultural Comparison | 1 | 2012 | 111 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 611 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2016 | 704 | 0.020 |
Why?
|
| Human Immunodeficiency Virus Proteins | 1 | 2012 | 4 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2012 | 9 | 0.020 |
Why?
|
| DNA Viruses | 1 | 2012 | 14 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2012 | 57 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 638 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 863 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1070 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 518 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 5 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 5 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 7 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 7 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2010 | 20 | 0.020 |
Why?
|
| Fluconazole | 1 | 2010 | 41 | 0.020 |
Why?
|
| Biopsy | 1 | 2011 | 177 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 1081 | 0.020 |
Why?
|
| Developing Countries | 1 | 2010 | 113 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 238 | 0.020 |
Why?
|
| Complement Activation | 1 | 2009 | 14 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 148 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 135 | 0.020 |
Why?
|
| Papillomaviridae | 1 | 2011 | 142 | 0.020 |
Why?
|
| Calorimetry, Indirect | 1 | 2009 | 9 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 416 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 352 | 0.020 |
Why?
|
| Spirometry | 1 | 2009 | 40 | 0.020 |
Why?
|
| Vaccines, Synthetic | 1 | 2009 | 80 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 82 | 0.020 |
Why?
|
| Oligopeptides | 1 | 2009 | 109 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 94 | 0.020 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2008 | 1 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 423 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2009 | 209 | 0.020 |
Why?
|
| Pyridines | 1 | 2009 | 139 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2009 | 282 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2008 | 102 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2009 | 190 | 0.020 |
Why?
|
| Karnofsky Performance Status | 1 | 2007 | 4 | 0.020 |
Why?
|
| Morbidity | 1 | 2007 | 97 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 876 | 0.020 |
Why?
|
| Placebos | 1 | 2006 | 41 | 0.020 |
Why?
|
| Liver | 1 | 2010 | 511 | 0.020 |
Why?
|
| Diet | 1 | 2012 | 826 | 0.020 |
Why?
|
| Mass Screening | 1 | 2011 | 541 | 0.020 |
Why?
|
| Tilt-Table Test | 1 | 2006 | 4 | 0.020 |
Why?
|
| Sample Size | 1 | 2006 | 28 | 0.010 |
Why?
|
| Respiration | 1 | 2006 | 56 | 0.010 |
Why?
|
| Delivery of Health Care | 1 | 2008 | 310 | 0.010 |
Why?
|
| Cell Line | 1 | 2009 | 1410 | 0.010 |
Why?
|
| Carnitine | 1 | 2004 | 7 | 0.010 |
Why?
|
| Insulin | 1 | 2006 | 258 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2004 | 134 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 2008 | 638 | 0.010 |
Why?
|
| Hip | 1 | 2003 | 3 | 0.010 |
Why?
|
| Osteonecrosis | 1 | 2003 | 8 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 71 | 0.010 |
Why?
|
| Neuroglia | 1 | 2004 | 133 | 0.010 |
Why?
|
| Anxiety | 1 | 2010 | 874 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1271 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2002 | 515 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2002 | 1542 | 0.010 |
Why?
|
| Apoptosis | 1 | 2003 | 1568 | 0.010 |
Why?
|